Oppenheimer analyst Jay Olson maintained a Buy rating on SAGE Therapeutics (NASDAQ:SAGE) on Wednesday, setting a price target of $94, which is approximately 26.60% above the present share price of $74.25.
Olson expects SAGE Therapeutics to post earnings per share (EPS) of -$2.03 for the fourth quarter of 2020.
The current consensus among 18 TipRanks analysts is for a Moderate Buy rating of shares in SAGE Therapeutics, with an average price target of $86.33.
The analysts price targets range from a high of $135 to a low of $60.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $1.64 million and a net profit of -$107.69 million. The company's market cap is $3.86 billion.
According to TipRanks.com, Oppenheimer analyst Jay Olson is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -1.1% and a 40.44% success rate.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.